The Global Lupus Market is expected to grow significantly over the forecast period. It is anticipated that the market held a market value of USD 1.48 billion in 2017 and is projected to grow at a CAGR of 11.2% over the forecast period. Lupus is a systemic autoimmune disease that causes inflammation throughout the body.  In patients with lupus, the immune system attacks healthy cells and tissues of the body which can result in damage to many parts of the body including the skin, joints, kidney, heart, lungs, blood vessels, and brain. The factors such as the rising prevalence of lupus, ongoing medical advancements in the treatment of systemic lupus erythematosus, increasing research and development activities are expected to drive market growth during the forecast period. According to the Lupus Foundation of America, about 1.5 million Americans have a form of lupus, and about 16,000 new cases are reported each year in the Americas. Despite the drivers, the factors such as strict government regulation and increasing prices of lupus drugs may hamper the market growth over the assessment period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6636

Currently, a large number of companies are present in the lupus market. The prominent market players are involved in the development of new products and product launches. For instance, in July 2017, GlaxoSmithKline received FDA approval for a new self-injectable formulation of Benlysta for the treatment of adult patients with systemic lupus erythematosus.  

Segmentation

The Global Lupus Market has been segmented into types, treatment, and end user. The global market, on the basis of type, has been segmented into systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus. The systemic lupus erythematosus segment is expected to hold the largest market share owing to the growing prevalence and increasing drug development in recent years.

On the basis of treatment, the market has been segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, corticosteroids, immunosuppressants, biologics, and other.

On the basis of end user, the market has been segmented into hospital & clinics, diagnostic laboratories, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The lupus market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European lupus market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The lupus market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The lupus market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key Players

Aurinia Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Sanofi, Lycera Corporation, Merck KGaA, and Eli Lily and Company are some of the key players in the global lupus market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/lupus-market-6636